State of Wisconsin Investment Board Acquires 19,550 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)

State of Wisconsin Investment Board raised its holdings in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 25.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,884 shares of the medical research company’s stock after acquiring an additional 19,550 shares during the quarter. State of Wisconsin Investment Board’s holdings in PRA Health Sciences were worth $10,796,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. BlackRock Inc. increased its holdings in PRA Health Sciences by 0.9% during the 1st quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock valued at $685,054,000 after acquiring an additional 52,524 shares in the last quarter. Vanguard Group Inc increased its holdings in PRA Health Sciences by 12.8% during the 3rd quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after acquiring an additional 658,191 shares in the last quarter. FMR LLC increased its holdings in PRA Health Sciences by 11.7% during the 4th quarter. FMR LLC now owns 2,588,853 shares of the medical research company’s stock valued at $238,071,000 after acquiring an additional 271,360 shares in the last quarter. Frontier Capital Management Co. LLC increased its holdings in PRA Health Sciences by 2.8% during the 1st quarter. Frontier Capital Management Co. LLC now owns 896,923 shares of the medical research company’s stock valued at $98,922,000 after acquiring an additional 24,207 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in PRA Health Sciences by 3.9% during the 4th quarter. Jennison Associates LLC now owns 866,731 shares of the medical research company’s stock valued at $79,705,000 after acquiring an additional 32,581 shares in the last quarter. Hedge funds and other institutional investors own 99.43% of the company’s stock.

Several research firms have weighed in on PRAH. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. Mizuho set a $100.00 price target on shares of PRA Health Sciences and gave the stock a “hold” rating in a report on Friday, May 3rd. SunTrust Banks lifted their price target on shares of PRA Health Sciences to $120.00 and gave the stock an “average” rating in a report on Monday, March 4th. ValuEngine downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. Finally, Wolfe Research began coverage on shares of PRA Health Sciences in a report on Tuesday, April 2nd. They set a “market perform” rating for the company. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. PRA Health Sciences presently has a consensus rating of “Hold” and an average price target of $113.22.

Shares of NASDAQ PRAH opened at $95.93 on Friday. The stock has a market cap of $6.33 billion, a PE ratio of 23.23, a PEG ratio of 1.30 and a beta of 1.08. PRA Health Sciences Inc has a 12 month low of $82.12 and a 12 month high of $121.98. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.15. The business had revenue of $722.00 million during the quarter, compared to the consensus estimate of $730.84 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.85 earnings per share. On average, research analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2019/06/15/state-of-wisconsin-investment-board-acquires-19550-shares-of-pra-health-sciences-inc-nasdaqprah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Does a trade war provide a risk to the global economy?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.